Mark G. Bandyk

Urology
653 W 8th St Fl 2
Jacksonville, FL 32209

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications

Role of Spatial Heterogeneity in Muscle-Invasive Bladder Cancer on Overall Survival and Immunotherapy Response.

Role of Spatial Heterogeneity in Muscle-Invasive Bladder Cancer on Overall Survival and Immunotherapy Response.

Journal: Cancers
Published: January 30, 2026

An integrated restricted mean survival time-based evaluation of efficacy, toxicity, and cost in first-line immunotherapy regimens for metastatic renal cell carcinoma.

An integrated restricted mean survival time-based evaluation of efficacy, toxicity, and cost in first-line immunotherapy regimens for metastatic renal cell carcinoma.

Journal: Urologic oncology
Published: January 09, 2026

Lutetium-177-PSMA radioligand therapy in metastatic hormone-sensitive prostate cancer: A systematic review of efficacy, safety, and combination strategies.

Lutetium-177-PSMA radioligand therapy in metastatic hormone-sensitive prostate cancer: A systematic review of efficacy, safety, and combination strategies.

Journal: Urologic oncology
Published: November 19, 2025

Histology-Specific Survival in Penile Squamous Cell Carcinoma: A SEER-Based Study Highlighting Human Papillomavirus Status and Prognostic Subtypes.

Histology-Specific Survival in Penile Squamous Cell Carcinoma: A SEER-Based Study Highlighting Human Papillomavirus Status and Prognostic Subtypes.

Journal: Cancers
Published: October 03, 2025

Genetics-Driven, Intensity-Modulated Adaptive Management of Patients With Metastatic Prostate Cancer.

Genetics-Driven, Intensity-Modulated Adaptive Management of Patients With Metastatic Prostate Cancer.

Journal: The Prostate
Published: June 29, 2025

Sex-based differences in genetic alterations and immune checkpoint inhibitor response in urothelial bladder cancer.

Sex-based differences in genetic alterations and immune checkpoint inhibitor response in urothelial bladder cancer.

Journal: Urologic oncology
Published: March 11, 2025

An RMST-based analysis of systemic therapy in muscle-invasive bladder cancer.

An RMST-based analysis of systemic therapy in muscle-invasive bladder cancer.

Journal: Urologic oncology
Published: March 09, 2025

Deep Learning Algorithms for Bladder Cancer Segmentation on Multi-Parametric MRI.

Deep Learning Algorithms for Bladder Cancer Segmentation on Multi-Parametric MRI.

Journal: Cancers
Published: May 24, 2024

MRI-based radiomic features for identifying recurrent prostate cancer after proton radiation therapy.

MRI-based radiomic features for identifying recurrent prostate cancer after proton radiation therapy.

Journal: Journal of applied clinical medical physics
Published: October 16, 2023

Extramural venous invasion: a novel magnetic resonance imaging biomarker for adverse pathology in bladder cancer.

Extramural venous invasion: a novel magnetic resonance imaging biomarker for adverse pathology in bladder cancer.

Journal: American journal of clinical and experimental urology
Published: December 09, 2022

Magnetic resonance imaging radiomic features for recurrent prostate cancer following proton radiation therapy-A pilot study.

Magnetic resonance imaging radiomic features for recurrent prostate cancer following proton radiation therapy-A pilot study.

Journal: Urologic oncology
Published: August 15, 2022

Can magnetic resonance imaging differentiate muscle invasion (T2) and lamina propria invasion (T1) urothelial carcinoma of the bladder? A systematic review and meta-analysis of Vesical Imaging-Reporting and Data System accuracy.

Can magnetic resonance imaging differentiate muscle invasion (T2) and lamina propria invasion (T1) urothelial carcinoma of the bladder? A systematic review and meta-analysis of Vesical Imaging-Reporting and Data System accuracy.

Journal: Current urology
Published: July 06, 2022
Showing 1-12 of 30

Last Updated: 09/26/2026